Get started
Live feed
·
PRReleasevia Quantisnow
Cel-Sci Corporation logo

CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

ByQuantisnow·Wall Street's wire, on your screen.
CVMCel-Sci Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CVM (Cel-Sci Corporation) and more on Quantisnow.